Suppr超能文献

透析治疗年限对死亡风险及长期透析存活者特征的影响。

Impact of years of dialysis therapy on mortality risk and the characteristics of longer term dialysis survivors.

作者信息

Okechukwu Chike Nathan, Lopes Antonio Alberto, Stack Austin G, Feng Shibao, Wolfe Robert A, Port Friedrich K

机构信息

Department of Internal Medicine, Epidemiology, and Cost Center, University of Michigan, Ann Arbor, MI, USA.

出版信息

Am J Kidney Dis. 2002 Mar;39(3):533-8. doi: 10.1053/ajkd.2002.31403.

Abstract

With improving survival and a decreasing probability of receiving a transplant, patients with end-stage renal disease (ESRD) are more likely to remain on hemodialysis therapy for more years than in the past. This study evaluates the effect of years on dialysis (vintage) on relative risk (RR) for death with and without adjustment for comorbidities and treatment factors. It also compares characteristics of patients on hemodialysis therapy for 7 years or longer with those on hemodialysis therapy for 1 to 7 years. Data were combined from two special US Renal Data System studies, the Case Mix Adequacy Study and Waves 1, 3, and 4 of the Dialysis Mortality and Morbidity Study. Excluding the first year of dialysis, 12,687 patients were studied during a 2-year follow-up, censoring at transplantation or loss to follow-up. Unadjusted analysis (vintage 1 to < 2 years as referent) showed that the risk for death remained nearly the same until the end of year 7 of dialysis therapy, after which the risk decreased significantly. However, with adjustment for demographics, comorbidities, and treatment factors, vintage was significantly associated with increased mortality risk during years 2 to less than 8 (RR = 1.12 to 1.30; P < 0.05). Vintage was independently associated with increased adjusted mortality among patients with and without diabetes until approximately 6 to less than 8 years of dialysis therapy. Patients on dialysis therapy for 7 years or longer were significantly (P < 0.05) more likely to be women, younger, and have lower phosphorus levels, higher hematocrits, and higher delivered dialysis doses. We conclude that adjusted mortality risk does not decrease with years on dialysis therapy, and modifiable factors deserve greater attention to improve survival among patients with ESRD with and without diabetes treated by hemodialysis.

摘要

随着终末期肾病(ESRD)患者生存率的提高以及接受移植的可能性降低,他们比过去更有可能接受更长时间的血液透析治疗。本研究评估透析年限(透析龄)对死亡相对风险(RR)的影响,同时考虑了合并症和治疗因素的调整情况。此外,还比较了接受血液透析治疗7年及以上患者与接受血液透析治疗1至7年患者的特征。数据来自美国肾脏数据系统的两项专项研究,即病例组合充分性研究以及透析死亡率和发病率研究的第1、3和4波。排除透析的第一年,在2年随访期间对12,687名患者进行了研究,随访终点为移植或失访。未调整分析(以透析龄1至<2年为参照)显示,在透析治疗第7年末之前,死亡风险几乎保持不变,此后风险显著降低。然而,在对人口统计学、合并症和治疗因素进行调整后,透析龄在第2至<8年期间与死亡率风险增加显著相关(RR = 1.12至1.30;P < 0.05)。在透析治疗约6至<8年之前,透析龄与糖尿病患者和非糖尿病患者调整后死亡率增加均独立相关。接受透析治疗7年及以上的患者显著(P < 0.05)更可能为女性、更年轻,且血磷水平更低、血细胞比容更高、透析剂量更高。我们得出结论,透析治疗年限增加并不会使调整后的死亡风险降低,对于改善接受血液透析治疗的糖尿病和非糖尿病ESRD患者的生存率而言,可改变的因素值得更多关注。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验